The Patent Finder

Altravax, Inc.

Also on record
Records under this name other than patents Altravax, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 6 of 6 · Back to Altravax, Inc.

PatentTitleStatus Expires Confidence
US 7,476,390Flavivirus antigens
Lapsed on the fee record
Ended Jan 13, 2021 · From the USPTO record
Lapsed on the fee recordEnded Jan 13, 2021From the USPTO record
US 9,353,158Hepatitis B virus vaccines
Lapsed on the fee record
Ended May 31, 2020 · From the USPTO record
Lapsed on the fee recordEnded May 31, 2020From the USPTO record
US 8,168,772Nucleic acids encoding novel chimeric C15/prM/E dengue virus immunogens prepared by DNA shuffling
Lapsed on the fee record
Ended May 1, 2020 · From the USPTO record
Lapsed on the fee recordEnded May 1, 2020From the USPTO record
US 8,158,131Recombinant dengue virus antigens comprising the C15 signal peptide, full-length PRM protein, and full-length E protein
Lapsed on the fee record
Ended Apr 17, 2020 · From the USPTO record
Lapsed on the fee recordEnded Apr 17, 2020From the USPTO record
US 9,186,397Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein
Lapsed on the fee record
Ended Nov 17, 2019 · From the USPTO record
Lapsed on the fee recordEnded Nov 17, 2019From the USPTO record
US 8,715,694Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein
Lapsed on the fee record
Ended May 6, 2018 · From the USPTO record
Lapsed on the fee recordEnded May 6, 2018From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited